Synaptic dysfunction represents one of the earliest and most critical pathological features of [Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease) ([Parkinson's disease](/diseases/parkinsons-disease)), preceding dopaminergic [neurons](/cell-types/neurons) loss and motor manifestations by years or even decades[@cheng2010]. The synapse, the fundamental unit of [neurons](/cell-types/neurons) communication, relies on precisely coordinated processes including neurotransmitter synthesis, vesicle trafficking, release, and recycling. In [Parkinson's disease](/diseases/parkinsons-disease), these intricate mechanisms become disrupted through multiple interconnected pathways, including [alpha-synuclein](/proteins/alpha-synuclein) pathology, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), lysosomal impairment, and [neuroinflammation](mechanisms/neuroinflammation)[^2. Understanding synaptic dysfunction provides crucial insights into disease progression and offers therapeutic targets for disease-modifying interventions.
Synaptic dysfunction represents one of the earliest and most critical pathological features of [Parkinson's disease](/diseases/parkinsons-disease)](/diseases/parkinsons-disease) ([Parkinson's disease](/diseases/parkinsons-disease)), preceding dopaminergic [neurons](/cell-types/neurons) loss and motor manifestations by years or even decades[@cheng2010]. The synapse, the fundamental unit of [neurons](/cell-types/neurons) communication, relies on precisely coordinated processes including neurotransmitter synthesis, vesicle trafficking, release, and recycling. In [Parkinson's disease](/diseases/parkinsons-disease), these intricate mechanisms become disrupted through multiple interconnected pathways, including [alpha-synuclein](/proteins/alpha-synuclein) pathology, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), lysosomal impairment, and [neuroinflammation](mechanisms/neuroinflammation)[^2. Understanding synaptic dysfunction provides crucial insights into disease progression and offers therapeutic targets for disease-modifying interventions.
The presynaptic terminal is a highly specialized compartment dedicated to neurotransmitter release. Dopaminergic [neurons](/cell-types/neurons) in the [substantia nigra](/brain-regions/substantia-nigra) pars compacta (SNc) possess unique synaptic properties that make them particularly vulnerable to [Parkinson's disease](/diseases/parkinsons-disease)-related insults[@sulzer2013]. The terminal contains synaptic vesicles organized in distinct pools: the readily releasable pool (RRP), the recycling pool, and the reserve pool. These vesicles undergo regulated exocytosis mediated by the SNARE complex, comprising syntaxin-1, SNAP-25, and synaptobrevin (VAMP2)[@jahn2018].
Dopamine synthesis occurs through a well-characterized enzymatic pathway beginning with tyrosine hydroxylase (TH), which converts tyrosine to L-DOPA, followed by aromatic L-amino acid decarboxylase (A[Alzheimer's disease](/diseases/alzheimers-disease)C), which converts L-DOPA to dopamine[@bezard2019]. The vesicular monoamine transporter 2 (VMAT2) packages dopamine into synaptic vesicles, protecting it from oxidative degradation and enabling regulated release. This compartmentalization is critical because cytosolic dopamine can undergo auto-oxidation, generating reactive oxygen species (ROS) that contribute to [oxidative stress](/mechanisms/oxidative-stress)[@asanuma2021].
Dopaminergic signaling is mediated primarily by two receptor families: D1-like receptors (D1, D5) that stimulate adenylyl cyclase, and D2-like receptors (D2, D3, D4) that inhibit it[@missale1998]. The basal ganglia express high levels of D1 and D2 receptors in distinct [neurons](/cell-types/neurons) populations—the direct pathway (D1-expressing) and indirect pathway (D2-expressing)—whose balanced activity is essential for normal motor control.
Alpha-synuclein (αSyn), the protein that forms Lewy bodies in [Parkinson's disease](/diseases/parkinsons-disease), directly disrupts synaptic function through multiple mechanisms[@bellucci2020]. In its monomeric form, αSyn localizes to presynaptic terminals where it regulates vesicle trafficking and neurotransmitter release. However, in [Parkinson's disease](/diseases/parkinsons-disease), αSyn undergoes aggregation into oligomers and fibrils that become toxic to synapses[@wong2017].
Research demonstrates that αSyn oligomers specifically bind to synaptic vesicles, impairing their ability to release neurotransmitter[@wang2017]. Studies using patient-derived [neurons](/cell-types/neurons) show that αSyn accumulation leads to reduced synaptic vesicle density, impaired vesicle recycling, and decreased neurotransmitter release probability[@schulzschaeffer2010]. The prion-like propagation of αSyn pathology to anatomically connected [neurons](/cell-types/neurons) explains the progressive spread of synaptic dysfunction throughout the nigrostriatal system[@desplats2012].
αSyn oligomers directly interact with synaptic ion channels, causing aberrant channel activity. In particular, voltage-gated calcium channels become dysregulated, leading to excessive calcium influx during synaptic activity[@hettiarachchi2023]. This calcium dysregulation triggers downstream toxic pathways including calpain activation and mitochondrial permeability transition. Studies show that αSyn oligomers form pore-like structures in synaptic membranes, causing membrane depolarization and neurotransmitter leak[@fusco2022].
Chronic αSyn pathology leads to progressive depletion of synaptic vesicle pools. The readily releasable pool (RRP) becomes particularly affected, with dramatic reductions in the number of fusion-competent vesicles[@janezic2023]. This depletion reflects both impaired vesicle recycling and reduced vesicle biogenesis. Ultrastructural studies of [Parkinson's disease](/diseases/parkinsons-disease) [brain](/brain-regions/overview) tissue reveal fewer synaptic vesicles per terminal and abnormal vesicle morphology[@kramer2007].
In response to αSyn accumulation, presynaptic terminals undergo structural remodeling. Synaptic active zones—the specialized regions where vesicle fusion occurs—become disorganized[@yuan2021]. Key active zone proteins including piccolo, bassoon, and rim1 show altered localization and expression. This structural disruption further impairs neurotransmitter release capacity.
Synaptic activity is extraordinarily energy-intensive, requiring constant ATP generation to maintain ion gradients, vesicle cycling, and receptor function[@surmeier2017]. Mitochondrial dysfunction in [Parkinson's disease](/diseases/parkinsons-disease) compromises synaptic energy supply through several mechanisms. Mutations in PINK1 and PARKIN, causal in familial [Parkinson's disease](/diseases/parkinsons-disease), impair mitophagy—the process by which damaged mitochondria are selectively eliminated[@pickrell2015]. Accumulation of defective mitochondria in synaptic terminals leads to ATP depletion, calcium dysregulation, and increased ROS production[@dodson2017].
Studies in mouse models with mitochondrial complex I inhibition (mimicking [Parkinson's disease](/diseases/parkinsons-disease) pathology) demonstrate dramatic synaptic deficits, including reduced spontaneous release, impaired vesicle replenishment, and altered short-term plasticity[@guzman2010]. Human neuroimaging studies using PET with mitochondrial complex I substrates confirm decreased synaptic energy metabolism in the basal ganglia of [Parkinson's disease](/diseases/parkinsons-disease) patients[@eckert2014].
The lysosomal-[autophagy](/mechanisms/autophagy) system is essential for synaptic protein turnover and organelle quality control[@mizuno2020]. Lysosomal dysfunction, observed in most [Parkinson's disease](/diseases/parkinsons-disease) cases due to GBA mutations, ATP13A2 deficiency, or other factors, impairs the degradation of αSyn and other aggregation-prone proteins[@moors2023]. This leads to their accumulation in synaptic terminals, where they interfere with normal synaptic function.
Autophagic flux impairment in dopaminergic [neurons](/cell-types/neurons) results in the accumulation of damaged organelles, including mitochondria and lysosomes themselves, within synaptic terminals[@dehay2016]. The resulting proteostatic stress compromises the synaptic vesicle cycle and neurotransmitter release machinery.
Dopaminergic [neurons](/cell-types/neurons) exhibit rhythmic pacemaking activity that relies on L-type calcium channels[@guzman2019]. This calcium influx, necessary for sustained firing, becomes dysregulated in [Parkinson's disease](/diseases/parkinsons-disease) due to αSyn-mediated channel dysfunction and mitochondrial impairment. Elevated cytosolic calcium accelerates mitochondrial ROS production and depletes ATP reserves[@chan2007].
Synaptic terminals are particularly vulnerable to calcium dysregulation because calcium triggers synaptic vesicle exocytosis and also activates calpains, calcium-dependent proteases that degrade synaptic proteins[@yamashita2020]. Excessive calcium influx leads to synaptic protein cleavage and impaired neurotransmission.
Microglial activation in [Parkinson's disease](/diseases/parkinsons-disease) contributes to synaptic dysfunction through both direct and indirect mechanisms. Activated [microglia](/cell-types/microglia) release pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6, which directly impair synaptic function[@lee2022]. These cytokines reduce synaptic vesicle release probability and alter postsynaptic receptor trafficking. Additionally, [microglia](/cell-types/microglia) phagocytose synaptic material in a process termed "synaptic pruning," which is enhanced in the inflamed [Parkinson's disease](/diseases/parkinsons-disease) [brain](/brain-regions/overview)[@zhou2024].
Complement system activation plays a key role in inflammation-mediated synaptic loss. C1q and C3 tagging of synapses targets them for [microglia](/cell-types/microglia)l elimination[@stevens2007]. Studies in [Parkinson's disease](/diseases/parkinsons-disease) models show increased complement deposition on dopaminergic synapses, correlating with synaptic loss severity[@foger2023].
Astrocytes play essential roles in synaptic maintenance, including neurotransmitter clearance, metabolic support, and ion homeostasis. In [Parkinson's disease](/diseases/parkinsons-disease), astrocyte dysfunction contributes to synaptic impairment through multiple mechanisms[@bobermin2022]. Reduced glutamate uptake leads to extrasynaptic glutamate accumulation and excitotoxicity. Impaired potassium buffering disrupts [neurons](/cell-types/neurons) resting membrane potentials. Altered astrocytic metabolism reduces lactate supply to [neurons](/cell-types/neurons), compromising synaptic energy requirements.
In [Parkinson's disease](/diseases/parkinsons-disease), striatal dopamine release is dramatically reduced due to the progressive loss of nigral [neurons](/cell-types/neurons). However, synaptic dysfunction precedes terminal loss, with studies demonstrating reduced dopamine release capacity in apparently intact [neurons](/cell-types/neurons)[@nirenberg2015]. This impairment involves:
Excessive glutamatergic signaling contributes to synaptic dysfunction and [neurons](/cell-types/neurons) death in [Parkinson's disease](/diseases/parkinsons-disease)[@ambrosi2014]. NMDA and AMPA receptor overactivation leads to excessive calcium influx, activating destructive enzymatic pathways. The subthalamic nucleus, a major glutamatergic output to the basal ganglia, becomes hyperactive in [Parkinson's disease](/diseases/parkinsons-disease), driving excitotoxic damage to dopaminergic [neurons](/cell-types/neurons)[@lang2004].
GABAergic transmission is altered in [Parkinson's disease](/diseases/parkinsons-disease), affecting both inhibitory and disinhibitory circuits[@iyer2019]. Reduced GABA release from inter[neurons](/cell-types/neurons) contributes to excessive [neurons](/cell-types/neurons) firing and network dysfunction. GABAergic synapse loss correlates with cognitive impairment in [Parkinson's disease](/diseases/parkinsons-disease) patients[@kalia2015].
Synaptic changes begin decades before clinical diagnosis. Studies in asymptomatic carriers of LRRK2 or GBA mutations show subtle synaptic alterations detectable by PET imaging of vesicular acetylcholine transporter (VAChT)[@pagano2022]. These early changes may represent compensatory mechanisms that eventually fail.
At diagnosis, approximately 50-70% of dopaminergic [neurons](/cell-types/neurons) have already been lost, with corresponding dramatic reductions in striatal dopamine release[@kalia2015a]. However, remaining terminals show profound functional impairment beyond what can be explained by [neurons](/cell-types/neurons) loss alone. This indicates that synaptic dysfunction is a major contributor to clinical deficits.
In advanced [Parkinson's disease](/diseases/parkinsons-disease), extensive synaptic loss occurs throughout the basal ganglia and cortical circuits[@rudnick2018]. This widespread synaptic degeneration explains the progressive development of motor complications (dyskinesias, freezing of gait) and non-motor symptoms (cognitive decline, autonomic dysfunction).
Synaptic dysfunction can be assessed using PET imaging of presynaptic terminals. Radiotracers targeting VMAT2 (e.g., ^18F-FP-DTBZ) provide quantitative measures of dopaminergic terminal integrity[@ko2020]. More recently, synaptic vesicle glycoprotein 2A (SV2A) PET ligands enable visualization of global synaptic loss[@matuskey2020].
Cerebrospinal fluid (CSF) biomarkers reflecting synaptic degeneration include neurogranin, SNAP-25, and synaptotagmin[@blennow2012]. These proteins are elevated in [Parkinson's disease](/diseases/parkinsons-disease) and correlate with disease severity and progression.
Transcranial magnetic stimulation (TMS) provides non-invasive assessment of cortical synaptic function. Motor evoked potential (MEP) measurements reveal altered cortical excitability in [Parkinson's disease](/diseases/parkinsons-disease)[@cantello2002]. Paired-pulse TMS protocols assess intracortical inhibition and facilitation, showing characteristic changes in [Parkinson's disease](/diseases/parkinsons-disease) patients[@berardelli2006].
Dopamine Replacement: Levodopa and dopamine agonists partially compensate for reduced synaptic dopamine but do not address underlying synaptic pathology[@fahn2004]. Long-term treatment leads to dyskinesias, partly due to non-physiological dopamine receptor stimulation.
Synaptic Function-Targeting Drugs: Several experimental approaches aim to restore synaptic function:
Genetic mouse models have provided critical insights into [Parkinson's disease](/diseases/parkinsons-disease)-related synaptic dysfunction. Models using viral αSyn overexpression, A53T mutant expression, or knock-in of [Parkinson's disease](/diseases/parkinsons-disease)-associated mutations demonstrate age-dependent synaptic deficits[@chesselet2012]. Conditional models allowing temporal control show that synaptic dysfunction occurs rapidly after αSyn accumulation, before [neurons](/cell-types/neurons) loss[@oaks2013].
MitoPark mice, with [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) restricted to dopaminergic [neurons](/cell-types/neurons), exhibit progressive synaptic deficits resembling human [Parkinson's disease](/diseases/parkinsons-disease)[@tereshchenko2014]. These models enable testing of synaptic-restoring therapies before irreversible [neurons](/cell-types/neurons) loss occurs.
While [Alzheimer's disease](/diseases/alzheimers-disease) is primarily characterized by amyloid and [tau](/proteins/tau) pathology, synaptic dysfunction is the strongest correlate of cognitive impairment[@selkoe2002]. Postsynaptic changes, particularly dendritic spine loss, predominate in [Alzheimer's disease](/diseases/alzheimers-disease), while presynaptic deficits are more prominent in [Parkinson's disease](/diseases/parkinsons-disease). This reflects the different proteinopathies underlying each disorder.
Motor neuron disease involves profound synaptic dysfunction at the neuromuscular junction and central synapses[@van2021]. Unlike [Parkinson's disease](/diseases/parkinsons-disease), where dopaminergic terminals are primarily affected, [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis) shows widespread synaptic loss affecting excitatory and inhibitory circuits.
DLB shares αSyn pathology with [Parkinson's disease](/diseases/parkinsons-disease) but shows more prominent cortical synaptic loss, correlating with cognitive fluctuations and visual hallucinations[@hurtig2000]. The distribution of synaptic pathology distinguishes [Parkinson's disease](/diseases/parkinsons-disease) [dementia](/diseases/dementia) from DLB.
Emerging technologies enabling synaptic proteomics and transcriptomics from individual [neurons](/cell-types/neurons) will reveal cell-type-specific vulnerability mechanisms[@li2024]. These approaches will identify novel therapeutic targets specific to vulnerable [neurons](/cell-types/neurons) populations.
Optogenetic tools allow precise manipulation of synaptic activity in model systems[@boyden2005]. Combining channelrhodopsin with [Parkinson's disease](/diseases/parkinsons-disease)-related genetic or pharmacologic insults enables mechanistic dissection of synaptic dysfunction.
Patient-derived induced pluripotent stem cells (iPSCs) differentiated into dopaminergic [neurons](/cell-types/neurons) provide human disease models for synaptic studies[@kriks2011]. These models recapitulate patient-specific vulnerabilities and enable personalized therapeutic testing.
Synaptic dysfunction represents a central pathogenic mechanism in [Parkinson's disease](/diseases/parkinsons-disease), beginning early in disease course and contributing to both motor and non-motor manifestations. The multiple converging pathways—αSyn pathology, [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), lysosomal impairment, calcium dysregulation, [neuroinflammation](/mechanisms/neuroinflammation), and astrocyte dysfunction—create a synergistic attack on synaptic integrity. Understanding these mechanisms provides crucial targets for disease-modifying therapies aimed at preserving synaptic function and preventing progressive neurodegeneration.
The preservation and restoration of synaptic function represents one of the most promising avenues for developing disease-modifying treatments for [Parkinson's disease](/diseases/parkinsons-disease). By targeting the earliest pathological events in [Parkinson's disease](/diseases/parkinsons-disease), therapeutic interventions may potentially slow or halt disease progression before irreversible [neurons](/cell-types/neurons) loss occurs.